Oncternal Therapeutics Inc. buy Brookline Capital Management
Start price
04.12.23
/
50%
€0.31
Target price
04.12.24
€1.85
Performance (%)
3.23%
Price
05.01.24
€0.32
Summary
This prediction is currently active. With a performance of 3.23%, the BUY prediction by Brookline_Capital_Ma for Oncternal Therapeutics Inc. is trending in the right direction. This prediction currently runs until 04.12.24. The prediction end date can be changed by Brookline_Capital_Ma at any time. Brookline_Capital_Ma has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Oncternal Therapeutics Inc. | - | - |
| iShares Core DAX® | -0.922% | -1.993% |
| iShares Nasdaq 100 | 0.371% | -0.868% |
| iShares Nikkei 225® | 2.224% | -5.187% |
| iShares S&P 500 | -0.026% | -0.918% |
Comments by Brookline_Capital_Ma for this prediction
In the thread Oncternal Therapeutics Inc. diskutieren
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) was upgraded by analysts at Brookline Capital Management from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock.
Ratings data for ONCT provided by MarketBeat
Stopped prediction by Brookline_Capital_Ma for Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.70
11.03.23
11.03.23
-
11.03.24
11.03.24
-62.03%
12.03.24
12.03.24
